Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Trial Profile

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CX-2029 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Diffuse large B cell lymphoma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms PROCLAIM-CX-2009-001; PROCLAIM-CX-2029
  • Sponsors CytomX Therapeutics
  • Most Recent Events

    • 31 May 2020 Peliminary results (n=34; as of 30 Nov 2019) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2020 According to a CytomX Therapeutics media release, Melissa L. Johnson is the Principal investigator of the study.
    • 29 May 2020 Results presented in the CytomX Therapeutics Media Release.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top